Home

John Lunger

CIK 1784487 · Chief Patient Supply Officer · last filed 2025-02-20

John Lunger is a Chief Patient Supply Officer who has filed 31 SEC Form 4 insider transactions across 3 companies since 2019. The most recent filing, for ADAP, was dated Feb 20, 2025. Across all open-market trades the lifetime net is −$218.0K, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

3

Total Filings

31

Lifetime Open-Market Net

-$218.0K

Filer Profile

Reported Address
C/O ADAPTIMMUNE THERAPEUTICS PLC
60 JUBILEE AVE, MILTON PARK
ABINGDON, OXFORDSHIRE, X0 OX14 4RX
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Adaptimmune Therapeutics PLC (ADAP) Delisted Chief Patient Supply Officer 7,510 $0.06 $435 -$218.0K 27 2025-02-20
GENOCEA BIOSCIENCES, INC. (GNCA) Delisted Director — $0.00 — $0 1 2022-03-07
ASND Chief Patient Supply Officer — $270.56 — $0 1 2019-08-05

Recent Filings

31 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-02-20 Adaptimmune Therapeutics PLC (ADAP) Delisted Grant (A) — $0 EDGAR
2025-01-17 — Notice (144) −5,584 -$3.2K EDGAR
2025-01-17 Adaptimmune Therapeutics PLC (ADAP) Delisted Sell (S) −5,584 -$3.2K EDGAR
2025-01-15 — Notice (144) −9,739 -$5.7K EDGAR
2025-01-15 Adaptimmune Therapeutics PLC (ADAP) Delisted Sell (S) −19,542 -$11.4K EDGAR
2024-01-17 Adaptimmune Therapeutics PLC (ADAP) Delisted Sell (S) −22,795 -$15.9K EDGAR
2024-01-17 Adaptimmune Therapeutics PLC (ADAP) Delisted Grant (A) — $0 EDGAR
2024-01-12 Adaptimmune Therapeutics PLC (ADAP) Delisted Sell (S) −9,229 -$7.8K EDGAR
2023-08-01 Adaptimmune Therapeutics PLC (ADAP) Delisted Sell (S) −3,096 -$2.8K EDGAR
2023-01-17 Adaptimmune Therapeutics PLC (ADAP) Delisted Sell (S) −4,440 -$8.2K EDGAR
Showing 1–10 of 31
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.